At the end of the second day of the emergency vaccination campaign, 3,355 students and eligible University community members had received the vaccine against meningitis type B.
1,396 people received the vaccine on Tuesday. 1,959 people received it on Monday.
The University expects to vaccinate 6,000 people in total, although it has bought 12,000 doses of the vaccine.
The vaccine, called Bexsero and made by Swiss pharmaceutical company Novartis, is not currently licensed for use in the United States. Bexsero has been approved in the European Union, Australia and Canada.
The Princeton outbreak of meningitis type B has affected seven students and one outside visitor since March 2013.